Who are BPI-16350's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): F14, HS-20137, HS-20089, HS-10296, HS-10234, TAS-120.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bpi-16350.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

BPI-16350 — Competitive Intelligence Brief

BPI-16350 (BPI-16350) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FGFR inhibitor. Area: Oncology.

phase 3 FGFR inhibitor FGFR (Fibroblast Growth Factor Receptor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BPI-16350 (BPI-16350) — Betta Pharmaceuticals Co., Ltd.. BPI-16350 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BPI-16350 TARGET	BPI-16350	Betta Pharmaceuticals Co., Ltd.	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)
F14	F14	Arthritis Innovation Corporation	marketed	FGFR inhibitor monoclonal antibody	FGFR (Fibroblast Growth Factor Receptor)
HS-20137	HS-20137	Hansoh BioMedical R&D Company	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)
HS-20089	HS-20089	Hansoh BioMedical R&D Company	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)
HS-10296	HS-10296	Jiangsu Hansoh Pharmaceutical Co., Ltd.	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)
HS-10234	HS-10234	Jiangsu Hansoh Pharmaceutical Co., Ltd.	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)
TAS-120	TAS-120	Taiho Oncology, Inc.	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FGFR inhibitor class)

Hansoh BioMedical R&D Company · 3 drugs in this class
Haisco Pharmaceutical Group Co., Ltd. · 2 drugs in this class
Allist Pharmaceuticals, Inc. · 2 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Hanmi Pharmaceutical Company Limited · 2 drugs in this class
Eisai Inc. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Beta Pharma Shanghai · 1 drug in this class
Guangdong Raynovent Biotech Co., Ltd · 1 drug in this class
Caliway Biopharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BPI-16350 — Competitive Intelligence Brief. https://druglandscape.com/ci/bpi-16350. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab